Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel.Dear Fellow Shareholders,2025 marked an important milestone for BioHarvest Sciences: our first full year as a NASDAQ-listed company, and we enter 2026 with an annualized revenue ...

Core Insights - Mountain Valley MD Holdings Inc. (MVMD) is focused on disciplined execution across its business lines, aiming for measured growth in product development and commercialization [1] Nutraceuticals - MVMD's Quicksome™ technology optimizes molecule delivery in sublingual nutraceutical applications, enhancing efficacy, precise dosing, and dose sparing [2][3] - The company has an exclusive manufacturing and licensing agreement with a U.S.-based GMP production partner to support Quicksome™ formulations [3] - MVMD is advancing its nutraceutical strategy through partnerships, including a novel testosterone formulation for men, expected to launch in the first half of 2026 [5] Agriculture - MVMD is commercializing its Agrarius™ plant signaling technology, which aims to increase crop yields and reduce fertilizer usage [8] - Trials in Brazil have shown that Agrarius-treated citrus orchards achieved over 50% productivity gains and improved resilience to stress [11][12] - The company is also conducting trials in Colombia, demonstrating improved pasture quality and vegetation health [17] Husbandry Animals and Aquatic Species - MVMD's Soluvec™ 1% formulation, utilizing Quicksol™ technology, aims to provide safer administration of ivermectin for husbandry animals and aquatic species [18] - The company has entered into a licensing agreement in Bangladesh for the production and distribution of Soluvec™ products [19] - Despite initial challenges in commercial traction, MVMD is focusing on royalty-based licensing opportunities for Soluvec™ [21][24]

A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support BUZZ BOMB™ will power Ashley's elite training, recovery, and lifestyle needs with its best-in-class product In partnering with Aspire's BUZZ BOMBâ"¢ brand, Ashley joins a decorated athlete and fitness trainer roster fueled by the brand's industry-leading commitment to innovation ESTERO, FL / ACCESS Newswire / December 18, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ( ...

Role Supports Synergy’s Expanding Presence in Mexico, Including Initial Product Shipments to Costco MexicoWESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. ...

PresentationWelcome to today's fireside chat with LifeVantage Corporation. I'm your host, Doug Lane, Managing Director and Consumer Analyst at Water Tower Research. Today, I'm joined by Steve Fife, President and CEO at LifeVantage; and Carl Aure, CFO. So welcome Steve and Carl.Douglas LaneWater Tower Research LLC LifeVantage is a world leader in using nutrigenomics to activate a healthy body mind and mood with science-backed products that include unique combinations of naturally occurring compounds. The com ...

LifeVantage Conference Summary Company Overview - **Company**: LifeVantage Corporation (NasdaqCM: LFVN) - **Industry**: Nutrigenomics and Direct Selling - **Business Model**: Direct-selling of premium-quality supplements, energy, and skincare products through independent consultants globally [4][5] Key Points and Arguments 2025 Performance and Strategic Direction - LifeVantage is recovering from inventory stockouts of the MindBody GLP-1 system and is exiting 2025 positively due to the LoveBiome acquisition [5][6] - The company has modernized its compensation plan and invested in technology to accelerate growth [5][6] - The acquisition of LoveBiome is highlighted as a significant achievement, emphasizing the alignment of vision and values between the two companies [6][7] LoveBiome Acquisition - LoveBiome's key product, P84, focuses on gut health and has shown impressive results in in vitro studies, with increases of over 1,000% in certain peptides [11][13] - The integration of LoveBiome consultants into LifeVantage's Evolve Compensation Plan has been successful, with training and incentives in place to facilitate the transition [19][20] Product Development and Research - LifeVantage distinguishes itself by focusing on activating the body's natural health processes rather than just supplementation [11][12] - The company plans to continue research on P84 and its synergistic benefits with existing products like Protandim and GLP-1 [14][24] Geographic Expansion - LifeVantage has paused geographic expansion in recent years but is now focusing on broadening its international presence, starting with a successful launch in Iceland [27][28] - Future expansions are planned, including potential launches in the Canary Islands and other markets [29][30] Financial Outlook and Capital Allocation - The company remains committed to share repurchases and dividends, with approximately $17 million available for share buybacks [33][35] - Capital allocation will prioritize investments in e-commerce and integration efforts related to LoveBiome [36][41] Upcoming Events and Initiatives - A global kickoff event is scheduled for January 2026, where a new theme and incentives will be announced, focusing on subscriptions for consultants and customers [23][24] - The company anticipates a global convention in October 2026, expected to feature product launches and recognition of achievements [45][46] Additional Important Information - LifeVantage's focus on subscriptions is seen as a key growth area, leveraging the benefits of recurring revenue [23] - The company is committed to continuous improvement in product strategy, compensation plans, and technology to support growth [27][33]

Core Insights - Exousia Pro, Inc. has launched its flagship nutraceutical product, Maxasome™, which is based on proprietary exosome-based delivery systems [1] - Maxasome™ is derived from 100% pure Exosome-Like Nanoparticles (ELNs) sourced from the Yellow Oyster Mushroom, known for its high value [1] - The product is designed as a multi-modal cytoprotective agent aimed at enhancing cellular defense and extending health span [1] Company Overview - Exousia Pro, Inc. is a clinical-stage biotechnology company focused on innovative delivery systems utilizing exosomes [1] - The company emphasizes the all-natural composition of its products, highlighting the use of ELNs from a specific mushroom species [1] Product Details - Maxasome™ is characterized as an unprecedented nutraceutical, indicating a unique position in the market [1] - The product aims to provide unparalleled cellular defense, suggesting a strong potential for health benefits [1]

Core Insights - Cosmos Health Inc. has seen significant share acquisitions by CEO Greg Siokas, who purchased 301,101 shares between November 19 and November 28, 2025, increasing his total ownership to 6,459,985 shares [1][2][3] - The company reported record-breaking Q3 2025 results, with strong growth across all core business segments, yet its valuation remains under pressure despite these achievements [2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, owning a portfolio of proprietary pharmaceutical and nutraceutical brands [4] - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA) [4] - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders enhanced by artificial intelligence technologies [4] Recent Developments - CEO Greg Siokas has expressed strong confidence in the company's future, stating that he has increased his ownership by over 3 million shares since the beginning of 2025, indicating a commitment to support the company's objectives [2][3] - The company is expanding its global distribution platform throughout Europe, Asia, and North America, with offices and distribution centers in Greece and the UK [4]

Core Insights - Mountain Valley MD Holdings Inc. (MVMD) has confirmed positive results from its Agrarius agricultural product trials, particularly in citrus and pasture grass, indicating progress towards commercialization [1][10] Citrus Trials in Brazil - MVMD collaborated with FARMATAC to evaluate the Agrarius product's impact on mature citrus orchards, focusing on Hamlin and Valencia orange varieties [2] - Preliminary results from younger citrus orchards show consistent or improved outcomes compared to mature tree trials, with results expected soon [3] - A significant finding is the reduction of visible symptoms of Huanglongbing (HLB), a disease severely affecting citrus production, suggesting Agrarius could be a scalable organic solution [4][5] Pasture Grass Trials in Colombia - MVMD is conducting a large-scale evaluation of pasture grass in partnership with FEDEGAN, targeting productivity and nutritional content across various regions [6][8] - Agrarius-treated Hamlin variety orchards showed a 15% increase in productivity, while Valencia variety orchards achieved a 49% yield increase compared to control groups [6] - The study indicates improved vegetation health and faster regrowth, potentially enhancing feed efficiency and milk production in cattle [8][9] Broader Crop Validation - Agrarius trials are expanding to include cotton, coffee, and other crops, reinforcing confidence in its performance across diverse agricultural conditions [10] - Results from various trials indicate significant yield improvements, such as a 14.8% increase in corn and an 18.49% increase in potatoes, supporting the technology's effectiveness [11]

Core Viewpoint - Promino Nutritional Sciences Inc. has successfully revoked a Failure-to-File Cease Trade Order (FFCTO) issued by the Ontario Securities Commission, allowing for the resumption of trading of its securities in Canada [1][2]. Company Updates - The FFCTO was initially issued on May 7, 2025, due to the company's failure to file its annual audited financial statements and related documents for the fiscal year ended December 31, 2024 [2]. - The company submitted the required filings on September 12, 2025, with amendments made on November 19, 2025, which are available for review on SEDAR+ [2]. - Promino has applied to the Canadian Securities Exchange to reinstate trading of its common shares and has committed to holding an annual meeting of shareholders by February 26, 2026 [3]. Product Information - Promino is a Canadian nutraceutical company focused on developing science-based products for muscle health, with its lead product being Rejuvenate Muscle Health™, which has a new formulation aimed at enhancing muscle mass [4]. - The company also offers Promino™, a performance supplement designed for athletes to aid in muscle recovery and strength building [4].